KCT0002477进行中（未招募）未知
A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix Tablet 1 mg and Champix® Tablet 1 mg in Healthy Adult Male Subjects
Jeil Pharmaceutical0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1) Healthy male older than 19 to 45 years at the time of screening
- •2) Body weight more than 50kg and Body Mass Index(BMI) 18~29 kg/m2
- •? BMI = (weight [kg])/(height [m])2
- •3. Subject judged to be eligible by physical examination and interview conducted according to the study protocol. Thus, Subject should not have congenital/chronic disease or pathological symptoms/findings
- •4. Subject judged to be eligible by clinical tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol
- •5. Subject who fully understands the clinical trials after in-depth explanation, volunteers to join the clinical trials and signs inform consent
排除标准
- •1) Subject currently with or has a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant
- •2) Subject with a history of significant hypersensitivity or clinically significant hypersensitivity reaction to varenicline and other drugs (aspirin, antibiotic…etc.)
- •3) Systolic blood pressure ?100mmHg or ? 150mmHg, diastolic blood pressure?55mmHg or ? 95mmHg
- •4) Subject with a history of gastrointestinal disease (i.e. Crohn’s disease, ulcer…etc.) or gastrointestinal surgery (not including, simple appendectomy or hernia surgery) that can affect drug absorption
- •5) Subject with the following results in the clinical laboratory tests
- •- Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 2 x upper limit of normal range
- •- Total Bilirubin > 2.0 mg/dl
- •- CK > 2 x upper limit of normal range
- •- eGFR < 60 mL/min/1.73m2
- •6) Subject who takes alcohol > 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can’t stop drinking during the clinical trials
- •7) Subject who smokes> 10 cigarettes/day or can’t stop smoking during the clinical trials
- •8) Taking medication involved in other clinical trials within 90 days before the first administration
- •9) Whole blood donation within 60 days or component blood donation within 30 days before the first administration
- •10) Taking metabolizing enzyme inducers or inhibitors such as barbitals within 30 days before the first administration
- •11) Taking Prescription drug (ETC) or oriental medicine within two weeks and any OTC within 2 weeks before the first administration
- •12) Subject with mental illness or substance abuse
- •13) Genetic muscle disease, or family history, or history of drug-induced rheumatoid arthritis.
- •14) Consumption of food which can significantly change the absorption, distribution, metabolism and excretion of a drug within 7 days before the first administration (such as grapefruit or its components)
- •15) Those who do not agree with the approved method of contraception during the clinical trial
- •16) Patients judged as inadequate and clinical trials to test self-determined target for any reason.
研究者
相似试验
已完成
不适用
A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Energia Tablet and Stimol® Solution in Healthy Adult Male SubjectsSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0003165kims pharmaceutical30
尚未招募
1 期
An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of ARIPAZ-5 (Aripiprazole 5 mg tablets) of the GPO, Thailand with ABILIFY (Aripiprazole 5 mg tablets) of Korea Otsuka Pharmaceutical Co., Ltd., Korea in Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20220811003The Government Pharmaceutical Organization52
进行中（未招募）
不适用
Bioequivalence study comparing Nevirapine Prolonged Release 400 mg tablets (Mylan Laboratories Limited) to reference drug Viramune Prolonged-Release Tablets 400 mg under fasting conditions in adult HIV-I Infected Patients stabilized on NevirapineCTRI/2015/02/005493MYLAN LABORATORIES LIMITED36
已完成
不适用
Pharmacokinetic study of two formulations of Azathioprine Tablets 50 mg in Adult Subjects with Rheumatoid Arthritis.CTRI/2018/07/014995Alkem Laboratories Ltd64
招募中
Unknown
To assess blood concentration of Olaparib Tablets 150 mg at different times in patients with Cancer following Multiple-doseCTRI/2023/04/051731Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)